Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US ...Middle East

STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand...

Hence then, the article about eisai completes rolling bla submission for subcutaneous maintenance dosing of leqembi lecanemab irmb in the us was published today ( Friday 01/11/2024 - 02:53 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US )

Also on site :

• Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest
• Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
• Tuya Smart Launches "Hey Tuya:" A Super AI Life Assistant Bringing Physical AI to Everyday Life